CAR-T Cell Manufacturing With Minimal Ex Vivo Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing engineered immune cells, such as CAR-T cells, often require extensive ex vivo expansion, which can lead to cell exhaustion and reduced efficacy.
Innovation Solution
A method involving a rapid CAR-T cell manufacturing process with limited ex vivo expansion (up to 200%) using a stimulatory agent and a retroviral vector, allowing for a one-to-two-day activation step and a one-day transduction step in a single vessel, resulting in improved in vitro and in vivo expansion and potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If extensive ex vivo expansion is performed to increase cell number, then productivity is improved, but cell exhaustion increases and reliability deteriorates
Solution Approach 1:
The patent extracts and removes the extensive ex vivo expansion step from the CAR-T cell manufacturing process. By taking out this problematic step, the method eliminates cell exhaustion while still achieving therapeutic efficacy through alternative approaches including in vivo expansion and reduced ex vivo manipulation.
Solution Approach 2:
The patent skips or reduces the ex vivo expansion step significantly. Instead of performing extensive expansion, the method uses minimal expansion (≤200%) and relies on in vivo expansion to achieve the necessary cell numbers, thereby avoiding the harmful effects of prolonged ex vivo culture.
2Productivity
If extensive ex vivo expansion is performed to increase cell number, then productivity is improved, but manufacturing time increases
Solution Approach 1:
The patent removes the time-consuming ex vivo expansion step from the manufacturing process. By extracting this step, the method reduces manufacturing time while maintaining productivity through in vivo expansion that occurs naturally after administration.
Solution Approach 2:
The patent performs preliminary transduction and activation steps efficiently, then relies on in vivo expansion to occur naturally after administration. This preliminary action approach eliminates the need for prolonged ex vivo expansion, reducing manufacturing time while maintaining cell numbers.
3Manufacturing precision
If multiple steps are performed to engineer and expand cells, then manufacturing precision is improved, but device complexity increases
Solution Approach 1:
The patent merges multiple process steps into a streamlined workflow. By combining transduction, activation, and minimal expansion into a unified process, the method reduces device complexity while maintaining manufacturing precision through integrated rather than sequential operations.
Solution Approach 2:
The patent extracts and removes unnecessary intermediate steps from the manufacturing process. By taking out excessive expansion steps and other redundant operations, the method simplifies the overall process while maintaining cell quality through essential steps only.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces CAR-T cells with enhanced in vivo anti-tumor efficacy and proliferation capacity, maintaining a high percentage of functional T-cell phenotypes and reducing cell exhaustion.
Implementation Method 1
contacting the population of T cells with a retroviral vector that comprises a nucleic acid molecule encoding the exogenous gene product
Implementation Method 2
the stimulatory agent comprises a CD3 binding domain
Data Source
AI summary
The present disclosure provides improved methods of producing engineered T cells that express an exogenous gene (e.g., CAR-T cells). T cells that express an exogenous gene and compositions comprising the same of the present technology are useful for treating various diseases, e.g., infection, autoimmune diseases, and tumors.